Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

AXDX

Accelerate Diagnostics Inc

May 22 • 02:47PM ET

1.06

Dollar change -0.02
Percentage change -1.87	%

Healthcare • Medical Devices • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-4.54	Insider Own	37.99%	Shs Outstand	14.57M	Perf Week	17.13%
Market Cap	23.37M	Forward P/E	-	EPS next Y	-1.25	Insider Trans	-1.17%	Shs Float	13.67M	Perf Month	11.58%
Income	-59.05M	PEG	-	EPS next Q	-0.43	Inst Own	20.95%	Short Float	2.36%	Perf Quarter	11.58%
Sales	12.17M	P/S	1.92	EPS this Y	62.83%	Inst Trans	-	Short Ratio	4.75	Perf Half Y	-79.42%
Book/sh	-1.18	P/B	-	EPS next Y	25.69%	ROA	-144.52%	Short Interest	0.32M	Perf Year	-85.83%
Cash/sh	0.71	P/C	1.48	EPS next 5Y	30.00%	ROE	-	52W Range	0.73 - 11.90	Perf YTD	-72.96%
Dividend Est.	-	P/FCF	-	EPS past 5Y	21.16%	ROI	-480.73%	52W High	-91.09%	Beta	0.63
Dividend TTM	-	Quick Ratio	1.29	Sales past 5Y	18.48%	Gross Margin	28.32%	52W Low	45.21%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	1.50	EPS Y/Y TTM	39.13%	Oper. Margin	-395.47%	RSI (14)	63.65	Volatility	12.22% 8.98%
Employees	134	Debt/Eq	-	Sales Y/Y TTM	-3.47%	Profit Margin	-485.31%	Recom	2.00	Target Price	1.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	56.66%	Payout	-	Rel Volume	1.54	Prev Close	1.08
Sales Surprise	-8.00%	EPS Surprise	-49.33%	Sales Q/Q	3.88%	Earnings	May 08 AMC	Avg Volume	67.97K	Price	1.06
SMA20	15.53%	SMA50	14.98%	SMA200	-70.42%	Trades		Volume	86,113	Change	-1.87%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-09-22	Downgrade	Craig Hallum	Buy → Hold	$5
Oct-08-20	Initiated	BTIG Research	Neutral
Aug-07-20	Upgrade	Craig Hallum	Hold → Buy	$20
Sep-27-19	Downgrade	JP Morgan	Neutral → Underweight	$16
Nov-07-18	Downgrade	JP Morgan	Overweight → Neutral
May-24-18	Initiated	Craig Hallum	Hold	$25
Dec-13-17	Downgrade	BTIG Research	Buy → Neutral
Jul-12-17	Resumed	BTIG Research	Buy	$34
Mar-24-16	Initiated	JP Morgan	Overweight	$17
Dec-16-15	Initiated	Piper Jaffray	Overweight

May-09-24 12:28PM	Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q1 2024 Earnings Call Transcript (Insider Monkey)
06:04AM	Q1 2024 Accelerate Diagnostics Inc Earnings Call (Thomson Reuters StreetEvents)
03:43AM	Accelerate Diagnostics Inc (AXDX) (Q1 2024) Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-08-24 09:57PM	AXDX Stock Earnings: Accelerate Diagnostics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:25PM	Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
05:22PM	Loading…
05:22PM	Accelerate Diagnostics: Q1 Earnings Snapshot (Associated Press Finance)
04:42PM	Accelerate Diagnostics Reports Preliminary First Quarter 2024 Financial Results (PR Newswire)
May-02-24 10:01AM	Will Accelerate Diagnostics (AXDX) Report Negative Q1 Earnings? What You Should Know (Zacks)
09:30AM	Accelerate Diagnostics Scheduled Call to Review 2024 First Quarter Results. (PR Newswire)
Apr-02-24 10:51AM	Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q4 2023 Earnings Call Transcript (Insider Monkey) +5.70%
Mar-29-24 05:57AM	Q4 2023 Accelerate Diagnostics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-28-24 09:53PM	AXDX Stock Earnings: Accelerate Diagnostics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
05:45PM	Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results (PR Newswire)
Mar-07-24 09:30AM	Accelerate Diagnostics Scheduled Call to Review 2023 Fourth Quarter and Full Year Results. (PR Newswire)
09:20AM	Loading…
Jan-19-24 09:20AM	Accelerate Diagnostics Announces Pricing of Approximately $15 Million Public Offering and Private Placement (PR Newswire) -23.36%
Jan-16-24 07:45AM	Accelerate Diagnostics Announces Launch of Proposed Public Offering (PR Newswire) -23.51%
Jan-07-24 08:00PM	Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2023 Results (PR Newswire)
Nov-29-23 08:43AM	Accelerate Diagnostics (AXDX) Expands in In Vitro Diagnostics (Zacks)
Nov-27-23 09:15AM	Accelerate Diagnostics Announces Collaboration for the Use of the Arc System in Combination With Brukers MALDI Biotyper (PR Newswire)
Nov-22-23 09:35AM	Accelerate Diagnostics (AXDX) Loses -25.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-11-23 10:44AM	Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 06:42PM	Accelerate Diagnostics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Accelerate Diagnostics Reports Third Quarter 2023 Results (PR Newswire)
Oct-30-23 09:30AM	Accelerate Diagnostics Scheduled Call to Review 2023 Third Quarter Results. (PR Newswire)
Oct-03-23 08:50AM	Accelerate Diagnostics (AXDX) Moves 12.7% Higher: Will This Strength Last? (Zacks)
Sep-14-23 11:01PM	Insider Sell: CEO Jack Phillips Sells 733 Shares of Accelerate Diagnostics Inc (GuruFocus.com)
Aug-11-23 05:59AM	Q2 2023 Accelerate Diagnostics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 05:30PM	Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:26PM	Accelerate Diagnostics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Accelerate Diagnostics Reports Second Quarter 2023 Financial Results (PR Newswire)
Jul-27-23 09:30AM	Accelerate Diagnostics Scheduled Call to Review 2023 Second Quarter Results (PR Newswire)
Jul-10-23 09:00AM	Accelerate Diagnostics Announces 1-for-10 Reverse Stock Split (PR Newswire) -6.29%
Jun-29-23 09:40AM	Is Accelerate Diagnostics (AXDX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-13-23 09:40AM	Is Akero Therapeutics (AKRO) Outperforming Other Medical Stocks This Year? (Zacks) -23.32%
09:00AM	Accelerate Diagnostics Announces Successful Completion of Debt Restructuring Support Agreement, Supporting Advancement of Next-Generation Platform Wave (PR Newswire)
07:03AM	Individual investors invested in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) up 45% last week, insiders too were rewarded (Simply Wall St.)
May-23-23 09:40AM	Is Accelerate Diagnostics (AXDX) Outperforming Other Medical Stocks This Year? (Zacks)
May-12-23 09:53AM	Q1 2023 Accelerate Diagnostics Inc Earnings Call (Thomson Reuters StreetEvents)
May-11-23 05:25PM	Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:20PM	Accelerate Diagnostics: Q1 Earnings Snapshot (AP Finance)
04:05PM	Accelerate Diagnostics Reports First Quarter 2023 Financial Results (PR Newswire)
09:09AM	Syneos Health (SYNH) Announces a $7.1 Billion Merger Agreement (Zacks)
May-10-23 11:18AM	Walgreens Boots (WBA) New Alliances Aid Growth, Cost Woe Stays (Zacks)
10:23AM	Penumbra (PEN) Hits 52-Week High: What's Driving the Rise? (Zacks)
09:23AM	Thermo Fisher (TMO) Partners With Pfizer to Expand NGS Testing (Zacks)
Apr-27-23 09:30AM	Accelerate Diagnostics scheduled call to review 2023 first quarter results (PR Newswire)
Apr-19-23 08:38AM	Zacks.com featured highlights include Disney, Casey's General Stores, OpGen, Accelerate Diagnostics and Nektar Therapeutics (Zacks)
Apr-17-23 06:38AM	Accelerate Diagnostics, Inc.'s (NASDAQ:AXDX) 38% Jump Shows Its Popularity With Investors (Simply Wall St.) +13.64%
Apr-03-23 12:00PM	Accelerate Diagnostics (AXDX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Apr-01-23 12:47PM	Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-29-23 05:25PM	Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Accelerate Diagnostics Reports Fourth Quarter and Full Year 2022 Financial Results (PR Newswire)
Mar-15-23 09:30AM	Accelerate Diagnostics scheduled call to review 2022 fourth quarter and full year results (PR Newswire)
Mar-14-23 08:00PM	Accelerate Diagnostics announces departure of CFO Steve Reichling and appointment of David Patience as replacement (PR Newswire) +5.88%
Mar-08-23 08:30AM	Accelerate Diagnostics announces appointment of Hany Massarany to Chairman of Board of Directors (PR Newswire)
Feb-06-23 05:23AM	A number of insiders bought Accelerate Diagnostics, Inc. (NASDAQ:AXDX) stock last year, which is great news for shareholders (Simply Wall St.)
Dec-19-22 01:32PM	Accelerate Diagnostics submits 510(K) application to FDA for Gram-negative menu expansion and breakpoint updates for the Accelerate PhenoTest® BC kit (PR Newswire) -9.72%
Nov-16-22 10:22AM	Accelerate Diagnostics Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.) -8.20%
Nov-14-22 04:05PM	Accelerate Diagnostics Reports Third Quarter 2022 Financial Results (PR Newswire) +5.63%
Oct-24-22 01:52PM	Why Accelerate Diagnostics Shares Are Plummeting Today? (Benzinga) -39.18%
10:02AM	Accelerate Diagnostics scheduled call to review 2022 third quarter results (PR Newswire)
Oct-19-22 01:27PM	Silk Road Medical (SILK) Stock Jumps 6.7%: Will It Continue to Soar? (Zacks)
Aug-23-22 08:02AM	Party Time: Brokers Just Made Major Increases To Their Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Earnings Forecasts (Simply Wall St.) +12.59%
Aug-19-22 04:50PM	Tucson-based Accelerate Diagnostics to raise $35M in stock offering (American City Business Journals) -49.40%
Aug-18-22 09:30PM	Accelerate Diagnostics Announces Pricing of Public Offering of Common Stock (PR Newswire) -27.19%
09:28AM	BD's (BDX) Latest Collaboration to Boost Patient Outcome (Zacks)
Aug-17-22 06:00PM	Accelerate Diagnostics Announces Proposed Public Offering of Common Stock (PR Newswire) +7.21%
Aug-15-22 02:41PM	Why Accelerate Diagnostics Shares Are Trading Higher Today (Benzinga) +26.42%
08:15AM	Accelerate Diagnostics Reports Second Quarter 2022 Financial Results (PR Newswire)
06:50AM	BD, Accelerate Diagnostics Announce Global Commercial Collaboration (PR Newswire)
Jul-28-22 07:09AM	What You Need To Know About Accelerate Diagnostics, Inc.'s (NASDAQ:AXDX) Investor Composition (Simply Wall St.)
Jul-25-22 09:30AM	Accelerate Diagnostics scheduled call to review 2022 second quarter results (PR Newswire)
Jul-11-22 08:00AM	Accelerate Diagnostics announces commercialization in Europe of its Accelerate Arc system having completed IVDR registration (PR Newswire)
Jun-13-22 06:55AM	Insiders may be rethinking their US$11m Accelerate Diagnostics, Inc. (NASDAQ:AXDX) investment now that the company has lost US$6.4m in value (Simply Wall St.)
May-23-22 09:30AM	Accelerate Diagnostics to Participate in 42nd Annual William Blair Growth Stock Conference on June 7, 2022 (PR Newswire) +6.81%
May-16-22 06:15PM	Accelerate Diagnostics (AXDX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -11.63%
04:05PM	Accelerate Diagnostics Reports First Quarter 2022 Financial Results (PR Newswire)
08:06AM	Accelerate Diagnostics announces commercialization of its Accelerate Arc system having completed IVD registration with FDA (PR Newswire)
May-12-22 06:25PM	Venus Concept (VERO) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -5.65%
May-10-22 05:55PM	Avinger (AVGR) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -5.02%
May-05-22 09:00AM	Examining Penny Stocks with Technical Analysis for May 2022 (Investopedia)
May-04-22 08:25AM	Avanos Medical (AVNS) Beats Q1 Earnings and Revenue Estimates (Zacks) -6.83%
Apr-29-22 09:30AM	Accelerate Diagnostics scheduled call to review 2022 first quarter results. (PR Newswire)
Apr-25-22 08:41AM	Accelerate Diagnostics Presents New Data at ECCMID 2022 Demonstrating Rapid and Accurate Results Using Automated Accelerate Arc Module and BC Kit (PR Newswire) +12.49%
Mar-28-22 08:05AM	Accelerate Diagnostics Announces Launch Of Accelerate Arc Module and BC Kit (PR Newswire)
Mar-15-22 06:15AM	What Does The Future Hold For Accelerate Diagnostics, Inc. (NASDAQ:AXDX)? These Analysts Have Been Cutting Their Estimates (Simply Wall St.)
Mar-08-22 05:45PM	Accelerate Diagnostics (AXDX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -7.35%
04:05PM	Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2021 Financial Results (PR Newswire)
Feb-24-22 09:30AM	Accelerate Diagnostics scheduled call to review 2021 fourth quarter and full year results (PR Newswire) +7.33%
Feb-15-22 03:01PM	Accelerate Diagnostics (AXDX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Feb-10-22 05:55PM	Sensus Healthcare, Inc. (SRTS) Beats Q4 Earnings and Revenue Estimates (Zacks)
Feb-02-22 09:30AM	Accelerate Diagnostics to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16, 2022, at 10:00 a.m. Eastern Time (PR Newswire)
Jan-31-22 05:05AM	What Is The Ownership Structure Like For Accelerate Diagnostics, Inc. (NASDAQ:AXDX)? (Simply Wall St.) +17.67%
Jan-28-22 09:38AM	Ironwood Financial, llc Buys Accelerate Diagnostics Inc, Vanguard Total Stock Market ETF, ... (GuruFocus.com)
Jan-13-22 09:15AM	Accelerate Diagnostics Announces Preliminary Fourth Quarter & Full-Year 2021 Financial Results (PR Newswire) -5.62%
Jan-12-22 09:15AM	Accelerate Diagnostics Wins Suzhou Innovation Award to Support Continued China Commercialization Efforts (PR Newswire)
Dec-29-21 09:30AM	Accelerate Diagnostics to Participate Virtually in 40th Annual J. P. Morgan Healthcare Conference on January 13, 2022 (PR Newswire)
Dec-01-21 04:07AM	The Independent Director of Accelerate Diagnostics, Inc. (NASDAQ:AXDX), Jack Schuler, Just Bought 5.8% More Shares (Simply Wall St.)
Nov-27-21 06:35AM	Accelerate Diagnostics (NASDAQ:AXDX) investors are sitting on a loss of 78% if they invested five years ago (Simply Wall St.)

Accelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The firm's products include Accelerate Pheno and Accelerate PhenoTest. The company was founded in 1982 and is headquartered in Tucson, AZ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mertz Larry Michael	Chief Technology Officer	May 20 '24	Option Exercise	0.00	1,283	0	82,114	May 21 07:03 PM
Mertz Larry Michael	Chief Technology Officer	May 20 '24	Sale	0.88	361	318	81,831	May 21 07:03 PM
Phillips Jack	Chief Executive Officer	Apr 17 '24	Option Exercise	0.00	59,928	0	189,654	Apr 18 04:10 PM
Phillips Jack	Chief Executive Officer	Apr 17 '24	Sale	0.78	26,735	20,853	162,919	Apr 18 04:10 PM
Phillips Jack	Chief Executive Officer	Apr 12 '24	Option Exercise	0.00	59,928	0	156,271	Apr 16 04:10 PM
Phillips Jack	Chief Executive Officer	Apr 12 '24	Sale	0.86	26,545	22,829	129,726	Apr 16 04:10 PM
Mertz Larry Michael	Chief Technology Officer	Apr 09 '24	Option Exercise	0.00	40,633	0	95,090	Apr 10 05:26 PM
Patience David	Chief Financial Officer	Apr 09 '24	Option Exercise	0.00	37,468	0	63,715	Apr 10 05:27 PM
Mertz Larry Michael	Chief Technology Officer	Apr 09 '24	Sale	0.87	13,984	12,166	81,106	Apr 10 05:26 PM
Patience David	Chief Financial Officer	Apr 09 '24	Sale	0.87	13,296	11,568	50,419	Apr 10 05:27 PM
Phillips Jack	Chief Executive Officer	Apr 04 '24	Option Exercise	0.00	35,523	0	112,230	Apr 05 04:26 PM
Mertz Larry Michael	Chief Technology Officer	Apr 04 '24	Option Exercise	0.00	2,866	0	55,435	Apr 05 04:29 PM
Phillips Jack	Chief Executive Officer	Apr 04 '24	Sale	0.88	15,887	13,981	96,343	Apr 05 04:26 PM
Mertz Larry Michael	Chief Technology Officer	Apr 04 '24	Sale	0.88	978	861	54,457	Apr 05 04:29 PM
Patience David	Chief Financial Officer	Feb 26 '24	Option Exercise	0.00	1,000	0	26,597	Feb 27 06:59 PM
Patience David	Chief Financial Officer	Feb 26 '24	Sale	0.96	350	336	26,247	Feb 27 06:59 PM
Phillips Jack	Chief Executive Officer	Feb 01 '24	Option Exercise	0.00	1,000	0	77,201	Feb 02 04:48 PM
Phillips Jack	Chief Executive Officer	Feb 01 '24	Sale	1.30	494	642	76,707	Feb 02 04:48 PM
Patience David	Chief Financial Officer	Dec 13 '23	Option Exercise	0.00	331	0	9,028	Dec 14 05:14 PM
Phillips Jack	Chief Executive Officer	Dec 13 '23	Option Exercise	0.00	1,721	0	60,274	Dec 14 05:15 PM
Phillips Jack	Chief Executive Officer	Dec 13 '23	Sale	4.39	739	3,244	59,535	Dec 14 05:15 PM
Patience David	Chief Financial Officer	Dec 13 '23	Sale	4.39	97	426	8,931	Dec 14 05:14 PM
Phillips Jack	Chief Executive Officer	Oct 13 '23	Option Exercise	0.00	1,721	0	58,310	Oct 16 05:16 PM
Patience David	Chief Financial Officer	Oct 13 '23	Option Exercise	0.00	331	0	8,559	Oct 16 05:17 PM
Phillips Jack	Chief Executive Officer	Oct 13 '23	Sale	5.83	734	4,279	57,576	Oct 16 05:16 PM
Patience David	Chief Financial Officer	Oct 13 '23	Sale	5.83	96	560	8,463	Oct 16 05:17 PM
Patience David	Chief Financial Officer	Sep 13 '23	Option Exercise	0.00	331	0	8,324	Sep 14 04:11 PM
Phillips Jack	Chief Executive Officer	Sep 13 '23	Option Exercise	0.00	1,722	0	57,322	Sep 14 04:13 PM
Phillips Jack	Chief Executive Officer	Sep 13 '23	Sale	6.53	733	4,786	56,589	Sep 14 04:13 PM
Patience David	Chief Financial Officer	Sep 13 '23	Sale	6.53	96	627	8,228	Sep 14 04:11 PM
Phillips Jack	Chief Executive Officer	Aug 14 '23	Sale	6.80	751	5,107	55,600	Aug 15 07:22 PM
Patience David	Chief Financial Officer	Aug 14 '23	Sale	6.80	95	646	7,993	Aug 15 07:22 PM
Phillips Jack	Chief Executive Officer	Aug 13 '23	Option Exercise	0.00	1,722	0	56,351	Aug 15 07:22 PM
Patience David	Chief Financial Officer	Aug 13 '23	Option Exercise	0.00	331	0	8,088	Aug 15 07:22 PM
Phillips Jack	Chief Executive Officer	Jul 13 '23	Option Exercise	0.00	1,722	0	55,358	Jul 17 05:11 PM
Patience David	Chief Financial Officer	Jul 13 '23	Option Exercise	0.00	330	0	7,849	Jul 17 05:20 PM
Phillips Jack	Chief Executive Officer	Jul 13 '23	Sale	6.90	729	5,030	54,629	Jul 17 05:11 PM
Patience David	Chief Financial Officer	Jul 13 '23	Sale	6.90	92	635	7,757	Jul 17 05:20 PM
Phillips Jack	Chief Executive Officer	Jun 22 '23	Option Exercise	0.00	62,160	0	563,624	Jun 26 06:48 PM
Phillips Jack	Chief Executive Officer	Jun 22 '23	Sale	0.71	27,262	19,356	536,362	Jun 26 06:48 PM
Phillips Jack	Chief Executive Officer	Jun 13 '23	Option Exercise	0.00	17,216	0	509,854	Jun 15 01:18 PM
Patience David	Chief Financial Officer	Jun 13 '23	Option Exercise	0.00	3,309	0	76,479	Jun 15 01:19 PM
Phillips Jack	Chief Executive Officer	Jun 13 '23	Sale	0.90	8,390	7,551	501,464	Jun 15 01:18 PM
Patience David	Chief Financial Officer	Jun 13 '23	Sale	0.90	1,287	1,158	75,192	Jun 15 01:19 PM
FRANCESCONI LOUISE	Director	May 31 '23	Option Exercise	0.00	75,949	0	75,949	Jun 01 08:31 PM
MASSARANY HANY	Director	May 31 '23	Option Exercise	0.00	75,949	0	75,949	Jun 01 08:30 PM
SCHULER JACK W	Director	May 31 '23	Option Exercise	0.00	75,949	0	75,949	Jun 01 08:29 PM
BURRIS WAYNE	Director	May 31 '23	Option Exercise	0.00	8,392	0	8,392	Jun 01 08:26 PM

Open in Screener

BDSX

Biodesix Inc

May 22 • 02:27PM ET

1.53

Dollar change -0.04
Percentage change -2.55	%

Healthcare • Diagnostics & Research • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-0.55	Insider Own	59.22%	Shs Outstand	96.24M	Perf Week	0.33%
Market Cap	175.48M	Forward P/E	-	EPS next Y	-0.27	Insider Trans	-0.17%	Shs Float	46.77M	Perf Month	19.53%
Income	-47.06M	PEG	-	EPS next Q	-0.09	Inst Own	17.27%	Short Float	0.74%	Perf Quarter	4.08%
Sales	54.85M	P/S	3.20	EPS this Y	42.97%	Inst Trans	15.77%	Short Ratio	2.44	Perf Half Y	7.75%
Book/sh	-0.06	P/B	-	EPS next Y	27.40%	ROA	-56.02%	Short Interest	0.35M	Perf Year	36.61%
Cash/sh	0.10	P/C	15.14	EPS next 5Y	-	ROE	-414.09%	52W Range	1.03 - 2.21	Perf YTD	-16.85%
Dividend Est.	-	P/FCF	-	EPS past 5Y	8.42%	ROI	-85.01%	52W High	-30.77%	Beta	1.24
Dividend TTM	-	Quick Ratio	0.87	Sales past 5Y	24.79%	Gross Margin	76.27%	52W Low	48.54%	ATR (14)	0.08
Dividend Ex-Date	-	Current Ratio	0.91	EPS Y/Y TTM	59.03%	Oper. Margin	-65.45%	RSI (14)	58.98	Volatility	2.22% 5.16%
Employees	217	Debt/Eq	-	Sales Y/Y TTM	34.69%	Profit Margin	-85.80%	Recom	1.00	Target Price	3.10
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	41.75%	Payout	-	Rel Volume	1.89	Prev Close	1.57
Sales Surprise	4.49%	EPS Surprise	1.48%	Sales Q/Q	63.63%	Earnings	May 08 AMC	Avg Volume	141.79K	Price	1.53
SMA20	6.47%	SMA50	9.65%	SMA200	-2.20%	Trades		Volume	221,370	Change	-2.55%

Date	Action	Analyst	Rating Change	Price Target Change
May-13-24	Initiated	TD Cowen	Buy	$2.80
May-03-24	Initiated	Lake Street	Buy	$3
Nov-17-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$21 → $11
Nov-23-20	Initiated	William Blair	Outperform
Nov-23-20	Initiated	Morgan Stanley	Overweight	$20
Nov-23-20	Initiated	Canaccord Genuity	Buy	$26
Nov-23-20	Initiated	BTIG Research	Buy	$22

May-21-24 06:00AM	Biodesix to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting (Business Wire)
May-10-24 05:59PM	Biodesix, Inc. (NASDAQ:BDSX) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:55PM	Biodesix Inc (BDSX) Surpasses Analyst Revenue Forecasts with Strong Q1 2024 Performance (GuruFocus.com)
May-09-24 03:46AM	Biodesix Inc (BDSX) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-08-24 09:00PM	BDSX Stock Earnings: Biodesix Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:20PM	Loading…
05:20PM	Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management (Business Wire)
May-07-24 06:00AM	Biodesix to Participate in the 2024 RBCCM Global Healthcare Conference (Business Wire)
Apr-24-24 06:00AM	Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024 (Business Wire)
Apr-09-24 05:00PM	Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting (Business Wire) -9.93%
Apr-05-24 07:17AM	Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement (Business Wire) -7.28%
Mar-25-24 06:00AM	Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center (Business Wire)
Mar-04-24 09:04AM	Biodesix, Inc. (NASDAQ:BDSX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-01-24 10:40PM	Q4 2023 Biodesix Inc Earnings Call (Thomson Reuters StreetEvents)
06:31AM	Biodesix Inc (BDSX) Reports Strong Growth in Lung Diagnostic Test Volume and Gross Profit Margin (GuruFocus.com)
06:00AM	Loading…
06:00AM	Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights (Business Wire)
Feb-26-24 06:00AM	Biodesix to Participate in the TD Cowen 44th Annual Health Care Conference (Business Wire)
Feb-16-24 06:00AM	Biodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024 (Business Wire) -5.73%
Feb-13-24 03:00AM	Biodesix Inc CEO Scott Hutton Sells 64,390 Shares (GuruFocus.com)
Jan-26-24 09:04AM	3 Penny Stocks to Turn $999 Into $1 Million: January 2024 (InvestorPlace)
Nov-14-23 06:00AM	Biodesix Enhances Access to Nodify Lung Testing with Launch of New Blood Draw Method (Business Wire)
Nov-09-23 06:00AM	Biodesix to Participate in Two Upcoming Investor Conferences in November (Business Wire) -6.39%
Nov-07-23 04:01PM	Biodesix Announces Third Quarter 2023 Results and Highlights (Business Wire)
Oct-24-23 06:00AM	Biodesix to Report Third Quarter 2023 Financial Results on November 7, 2023 (Business Wire) -5.00%
Oct-03-23 06:00AM	Biodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual Meeting (Business Wire)
Sep-07-23 06:00AM	Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer (Business Wire)
Sep-05-23 06:00AM	Biodesix to Participate in Two Upcoming Investor Conferences in September (Business Wire) -11.76%
Aug-22-23 06:00AM	Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer (Business Wire)
Aug-09-23 10:25AM	Biodesix, Inc. (NASDAQ:BDSX) Q2 2023 Earnings Call Transcript (Insider Monkey) -15.62%
Aug-08-23 08:38AM	Q2 2023 Biodesix Inc Earnings Call (Thomson Reuters StreetEvents)
05:15PM	Loading…
Aug-07-23 05:15PM	Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Biodesix Announces Second Quarter 2023 Results and Highlights (Business Wire)
Aug-01-23 06:00AM	Biodesix to Participate in the Canaccord Genuity 43rd Annual Growth Conference (Business Wire) +20.17%
Jul-26-23 07:58AM	Biodesix (NASDAQ:BDSX) investors are sitting on a loss of 49% if they invested a year ago (Simply Wall St.)
Jul-24-23 06:00AM	Biodesix to Report Second Quarter 2023 Financial Results on August 7, 2023 (Business Wire)
Jul-12-23 06:00AM	Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules (Business Wire)
Jul-06-23 09:11AM	Biodesix Awarded Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services (Business Wire)
Jun-27-23 06:00AM	Biodesix Completes Enrollment of INSIGHT Study Assessing Clinical Utility of the VeriStrat® Blood-Based Host Immune Classifier (Business Wire) -5.83%
Jun-01-23 06:00AM	Biodesix Announces Three Abstracts to Be Presented at ASCO 2023 Annual Meeting (Business Wire)
May-31-23 06:00AM	Biodesix to Participate in William Blairs 43rd Annual Growth Stock Conference (Business Wire)
May-28-23 08:09AM	Jack Schuler Spends US$65k On Biodesix Stock \ (Simply Wall St.)
May-25-23 06:00AM	Biodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® Testing (Business Wire) +5.30%
May-24-23 06:00AM	Biodesix, Inc. Chief Financial Officer Robin Harper Cowie Appointed to Colorado BioScience Association's Board of Directors (Business Wire) +12.68%
May-18-23 07:00AM	Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference (Business Wire) -5.79%
May-12-23 11:10AM	Q1 2023 Biodesix Inc Earnings Call (Thomson Reuters StreetEvents) -12.28%
May-11-23 05:25PM	Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Biodesix Announces First Quarter 2023 Results and Highlights (Business Wire)
May-09-23 06:15PM	Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-27-23 06:00AM	Biodesix to Report First Quarter 2023 Financial Results on May 11, 2023 (Business Wire)
Apr-12-23 06:53AM	Insiders of Biodesix, Inc. (NASDAQ:BDSX) must be frustrated after market cap dropped US$16m since recent purchases (Simply Wall St.)
Mar-15-23 09:31AM	Bullish Biodesix, Inc. (NASDAQ:BDSX) insiders filled their treasuries with US$34m worth of stock over last year (Simply Wall St.) +15.24%
Mar-08-23 07:14AM	Biodesix, Inc. (NASDAQ:BDSX) Q4 2022 Earnings Call Transcript (Insider Monkey) -5.06%
Mar-06-23 07:25AM	Biodesix, Inc. (BDSX) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -10.00%
06:00AM	Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and Highlights (Business Wire)
Feb-28-23 06:00AM	Biodesix to Participate at Cowens 43rd Annual Healthcare Conference (Business Wire)
Feb-21-23 06:00AM	Biodesix to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023 (Business Wire)
Feb-16-23 06:27AM	Even after rising 15% this past week, Biodesix (NASDAQ:BDSX) shareholders are still down 39% over the past year (Simply Wall St.) +5.72%
Dec-19-22 06:00AM	Biodesix Announces First Four Private Payer Coverage Policies for the Nodify XL2® Test (Business Wire) +5.88%
Dec-16-22 04:01PM	Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors (Business Wire)
Dec-12-22 06:00AM	Biodesix Ranked Top Proteomics Solutions Company by Life Sciences Review Magazine (Business Wire) +8.57%
Nov-21-22 04:01PM	Biodesix Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares (Business Wire) -7.14%
Nov-17-22 12:26AM	Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock (Business Wire) +23.48%
Nov-16-22 04:05PM	Biodesix Announces Proposed Public Offering of Common Stock (Business Wire) +8.49%
04:01PM	Biodesix Announces Senior Secured Financing Agreement with Perceptive Advisors for Up to $50 Million (Business Wire)
Nov-10-22 09:00AM	Biodesix Presents New Data from the INSIGHT Study at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting (Business Wire)
Nov-09-22 05:33AM	Biodesix Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.) -6.42%
Nov-03-22 07:15AM	Biodesix, Inc. (BDSX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
06:00AM	Biodesix Announces Third Quarter 2022 Results and Highlights (Business Wire)
Oct-20-22 06:00AM	Biodesix to Report Third Quarter 2022 Financial Results on November 3, 2022 (Business Wire)
Oct-17-22 05:05PM	Boulder's Biodesix snags $20M contract, plans move to larger space in Louisville (American City Business Journals)
06:00AM	Biodesix Awarded U.S. Federal Supply Schedule Contract for Its Comprehensive Lung Cancer Diagnostic Testing Solutions (Business Wire)
Oct-12-22 06:00AM	Biodesix to Present Data at the CHEST 2022 Annual Meeting Demonstrating High Sensitivity of the Nodify XL2® Blood-Based Lung Nodule Test in Various Patient Populations, Including Individuals Participating in Lung Cancer Screening Programs (Business Wire) -7.09%
Oct-11-22 06:00AM	Biodesix Announces Preliminary Revenue for Third Quarter 2022 (Business Wire)
Sep-06-22 06:00AM	Biodesix to Participate in Two Upcoming Investor Conferences in September (Business Wire) -6.56%
Aug-09-22 06:00AM	Biodesix Named a Top 100 Healthcare Technology Company of 2022 (Business Wire) -13.62%
Aug-06-22 04:30AM	Biodesix, Inc. (BDSX) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-04-22 07:15AM	Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:00AM	Biodesix Announces Second Quarter 2022 Results and Highlights (Business Wire)
Aug-03-22 06:00AM	Biodesix to Present at the Canaccord Genuity 42nd Annual Growth Conference (Business Wire) +5.34%
Jul-30-22 10:44AM	Biodesix, Inc. (NASDAQ:BDSX) insiders placed bullish bets worth US$21m in the last 12 months (Simply Wall St.)
Jul-20-22 06:00AM	Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint Inhibitors (Business Wire)
Jul-19-22 06:00AM	Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022 (Business Wire)
Jun-22-22 09:19AM	Sotera Health Company (SHC) Stock Jumps 6.5%: Will It Continue to Soar? (Zacks)
Jun-15-22 10:11AM	Investors in Biodesix (NASDAQ:BDSX) have unfortunately lost 90% over the last year (Simply Wall St.)
Jun-07-22 06:00AM	Biodesix Obtains Medicare Coverage for the Nodify CDT® Lung Nodule Test (Business Wire) +16.23%
Jun-03-22 06:00AM	Biodesix Announces Research Agreement with Top US Cancer Center (Business Wire)
Jun-01-22 06:00AM	Biodesix to Present at the 42nd Annual William Blair Growth Stock Conference (Business Wire) -6.76%
May-17-22 06:00AM	Biodesix to Present at the H.C. Wainwright Global Investment Conference (Business Wire)
May-12-22 06:00AM	Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to be Presented at ATS 2022 International Conference (Business Wire) +6.29%
May-11-22 07:15AM	Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -15.41%
06:00AM	Biodesix Announces First Quarter 2022 Results and Highlights (Business Wire)
Apr-27-22 06:00AM	Biodesix to Report First Quarter 2022 Financial Results on May 11, 2022 (Business Wire)
Apr-12-22 08:58AM	BioMed Stocks On the Move: Nova Mentis, PolarityTE, Biodesix and PharmaDrug; Life Sciences Leaders Report Latest Advances in Regenerative Tissue Technology, New Drugs for Cancers, Glaucoma, and Autism, and Diagnostics. (GlobeNewswire) +21.38%
Apr-11-22 06:00AM	Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term Loan (Business Wire) -5.36%
Mar-29-22 06:00AM	Biodesix Announces Publication Further Validating the Use of Liquid Biopsies and NGS Techniques to Provide Clinical Information for Patients With Cancer (Business Wire)
Mar-19-22 09:19AM	Analysts' Revenue Estimates For Biodesix, Inc. (NASDAQ:BDSX) Are Surging Higher (Simply Wall St.)
Mar-15-22 10:00AM	Here's Why Biodesix, Inc. (BDSX) Looks Ripe for Bottom Fishing (Zacks)
Mar-14-22 07:15AM	Biodesix, Inc. (BDSX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
06:00AM	Biodesix Announces Fourth Quarter and Year End 2021 Results and Highlights (Business Wire)
Mar-07-22 04:01PM	Biodesix Announces Common Stock Purchase Agreement for up to $50 Million with Lincoln Park Capital (Business Wire)

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Boulder, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hutton Scott	President & CEO	May 09 '24	Sale	1.48	3,764	5,569	483,780	May 10 05:04 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	May 09 '24	Sale	1.48	980	1,450	171,680	May 10 05:04 PM
O'Kane Kieran	Chief Commercial Officer	May 09 '24	Sale	1.48	468	692	75,524	May 10 05:05 PM
Pestano Gary Anthony	Chief Development Officer	May 09 '24	Sale	1.48	434	642	124,248	May 10 05:06 PM
Vazquez Chris	Chief Accounting Officer	May 09 '24	Sale	1.48	244	361	9,915	May 10 05:06 PM
Hutton Scott	President & CEO	Feb 12 '24	Sale	1.66	29,708	49,455	465,011	Feb 12 09:45 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	Feb 12 '24	Sale	1.66	8,699	14,481	169,410	Feb 12 09:44 PM
O'Kane Kieran	Chief Commercial Officer	Feb 12 '24	Sale	1.66	5,412	9,009	68,005	Feb 12 09:45 PM
Pestano Gary Anthony	Chief Development Officer	Feb 12 '24	Sale	1.66	5,022	8,360	123,250	Feb 12 09:45 PM
Vazquez Chris	Chief Accounting Officer	Feb 12 '24	Sale	1.66	922	1,535	9,548	Feb 12 09:46 PM
Hutton Scott	President & CEO	Feb 09 '24	Sale	1.92	34,682	66,472	494,719	Feb 12 09:45 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	Feb 09 '24	Sale	1.92	10,156	19,465	178,109	Feb 12 09:44 PM
O'Kane Kieran	Chief Commercial Officer	Feb 09 '24	Sale	1.92	6,319	12,111	73,417	Feb 12 09:45 PM
Pestano Gary Anthony	Chief Development Officer	Feb 09 '24	Sale	1.92	5,862	11,235	128,272	Feb 12 09:45 PM
Vazquez Chris	Chief Accounting Officer	Feb 09 '24	Sale	1.92	1,077	2,064	10,470	Feb 12 09:46 PM
Hutton Scott	President & CEO	Nov 10 '23	Sale	1.23	1,883	2,308	329,428	Nov 13 04:50 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	Nov 10 '23	Sale	1.23	491	602	136,573	Nov 13 04:50 PM
O'Kane Kieran	Chief Commercial Officer	Nov 10 '23	Sale	1.23	235	288	47,712	Nov 13 04:50 PM
Pestano Gary Anthony	Chief Development Officer	Nov 10 '23	Sale	1.23	218	267	104,501	Nov 13 04:51 PM
Vazquez Chris	Chief Accounting Officer	Nov 10 '23	Sale	1.23	108	132	6,251	Nov 13 04:51 PM
Hutton Scott	President & CEO	Nov 09 '23	Sale	1.27	1,882	2,391	331,311	Nov 13 04:50 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	Nov 09 '23	Sale	1.27	491	624	137,064	Nov 13 04:50 PM
O'Kane Kieran	Chief Commercial Officer	Nov 09 '23	Sale	1.27	234	297	47,947	Nov 13 04:50 PM
Pestano Gary Anthony	Chief Development Officer	Nov 09 '23	Sale	1.27	217	276	104,719	Nov 13 04:51 PM
Vazquez Chris	Chief Accounting Officer	Nov 09 '23	Sale	1.27	107	136	6,359	Nov 13 04:51 PM
SCHULER JACK W	Director	Aug 23 '23	Buy	1.71	87,500	149,240	30,707,722	Aug 23 06:56 PM
SCHULER JACK W	Director	Aug 22 '23	Buy	1.67	8,307	13,859	30,620,222	Aug 23 06:56 PM
SCHULER JACK W	Director	Aug 21 '23	Buy	1.64	32,556	53,411	30,611,915	Aug 23 06:56 PM
Hutton Scott	President & CEO	Aug 10 '23	Sale	1.27	6,889	8,728	318,013	Aug 10 07:28 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	Aug 10 '23	Sale	1.27	1,788	2,265	131,535	Aug 10 07:27 PM
O'Kane Kieran	Chief Commercial Officer	Aug 10 '23	Sale	1.27	849	1,076	46,692	Aug 10 07:28 PM
Pestano Gary Anthony	Chief Development Officer	Aug 10 '23	Sale	1.27	786	996	103,558	Aug 10 07:29 PM
Vazquez Chris	Chief Accounting Officer	Aug 10 '23	Sale	1.27	279	353	5,865	Aug 10 07:30 PM
Hutton Scott	President & CEO	Aug 09 '23	Sale	1.39	6,893	9,570	324,902	Aug 10 07:28 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	Aug 09 '23	Sale	1.39	1,789	2,484	133,323	Aug 10 07:27 PM
O'Kane Kieran	Chief Commercial Officer	Aug 09 '23	Sale	1.39	850	1,180	47,541	Aug 10 07:28 PM
Pestano Gary Anthony	Chief Development Officer	Aug 09 '23	Sale	1.39	787	1,093	104,344	Aug 10 07:29 PM
Vazquez Chris	Chief Accounting Officer	Aug 09 '23	Sale	1.39	280	389	6,144	Aug 10 07:30 PM
SCHULER JACK W	Director	May 31 '23	Buy	1.35	14,792	20,006	20,589,853	Jun 01 03:00 PM
SCHULER JACK W	Director	May 30 '23	Buy	1.36	11,849	16,150	20,575,061	Jun 01 03:00 PM
SCHULER JACK W	Director	May 25 '23	Buy	1.36	52,508	71,280	20,563,212	May 30 03:03 PM
SCHULER JACK W	Director	May 24 '23	Buy	1.25	35,308	43,980	20,510,704	May 26 03:00 PM
SCHULER JACK W	Director	May 23 '23	Buy	1.15	56,782	65,066	20,475,396	May 25 03:00 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

AXDX

Accelerate Diagnostics Inc

BDSX

Biodesix Inc

Upgrade your FINVIZ experience